Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane

Trauma Clinical Trial

Official title:

Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03521258
• Other study ID #: 9167
• Status: Recruiting
• Phase: N/A
• Start date: February 2016
• Est. completion date: February 2019

Study information

• Verified date: April 2018
• Source: Louisiana State University Health Sciences Center in New Orleans
• Contact: Frank Lau, MD
• Phone: 504-412-1240
• Email: flau[@]lsuhsc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Extremity wounds with exposed critical structures, including bone and tendon are a major burden on the American healthcare system with limited treatment options. Free Flap reconstructions of lower extremity wounds have an increased failure rate in comparison to elective free flap procedures.These procedures are long and are associated with a high cost of care, prolonged hospital stays, and are limited by the need for surgical specialist availability and patient vessels suitable for anastomoses. This study will use a new treatment modality which is a commercially ready human amniotic membrane allograft (EpiFix) to promote a granulation tissue wound base that will be suitable for skin grafting, thus forgoing the need for a flap-based for reconstruction. The study goals are to reduce the overall cost of providing definitive treatment by decreasing operative time, length of hospital stay, decrease the need for intensive nursing care and rehabilitation. This study will aim to provide a treatment option that is readily accessible to all patients with these complex wounds in any healthcare setting across the country.

Description:

53 patients ages 18 and over , presenting with wounds with exposed critical structures (bone and/or tendon) will be enrolled in the study and randomized into one of two groups. 21 patients will be in the standard treatment group (Flap based reconstruction) and 32 patients will be in the dHACM (EpiFix) + skin grafting treatment group (Experimental). Exclusion criteria includes exposed implanted hardware (surgical plates), anticipated need for future surgical procedures through the same wound, wounds resulting from surgical removal of malignancy, and patients who are not free flap candidates.

Data will be collected upon enrollment including:

Background and demographic information Wound size and severity Pain level Medication use Photographs of wound

Flap Reconstruction group (Standard of Care):

Patients in this group will have any dead, damaged or infected tissue removed from the wound and a negative pressure wound dressing will be applied until the wound is clean and adequate for flap reconstruction. Following flap reconstruction, patients typically require a 36-48 hour intensive care unit admission for flap monitoring and 5 days to bed rest to allow for proper healing. If the flap is successful, a dangle protocol will occur until patient increases the dependent position. Once the dangle protocol is completed, patients may require inpatient physical/occupational therapy prior to discharge from the hospital. If patient is not healing the physician may discuss other treatment options including crossing over to the EpiFix arm or amputation.

EpiFix and Skin Graft group:

Patients in this group will have any dead, damaged or infected tissue removed from wound. Once it is free from infection, a thin tissue (EpiFix) will be applied directly to the open wound. This will be covered by sterile wound dressing. After approximately 5-7 days the wound will be assessed for suitability of split thickness skin grafting. If adequately healed, skin grafting will be performed. After 5 days, the graft will be evaluated and if successful, the patient will be discharged home or to a rehab facility. If the wounds are not adequate for skin grafting, additional damaged tissue will removed and EpiFix will be placed until the wound is suitable for grafting. If you do not heal sufficiently the physician will discuss other treatment options including cross over to the standard of care Free Flap or amputation.

Study staff will evaluate the wound twice a week for the first 2 weeks, then once a week until 6 weeks. At this point, the patient will be followed every 4 weeks up to 22 weeks. Visits to the clinic will include wound measurements, photos, pain scale and evaluation of any infection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 53
• Est. completion date: February 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Wound includes exposed critical structures (tendon and/or bone)

• Patient is candidate flap reconstruction

• Patient is candidate for limb salvage

Exclusion Criteria:

• Wound involves weight-bearing surfaces (e.g. heel or forefoot wounds),

• Exposed implanted hardware (e.g. surgical plates)

• Anticipated need for future surgical procedures through the same wound

• Wounds resulting from surgical removal of malignancy

• Patients who are not flap candidates (e.g. severe peripheral vascular disease)

• Patients who are not limb salvage candidates (e.g. insensate or ischemic limbs).

Related Conditions & MeSH terms

• Injury
• Limb Salvage
• Soft Tissue Injuries
• Trauma
• Wounds
• Wounds and Injuries

Intervention

Device:
• Dehydrated Human Amnion/Chorion Membrane

Procedure:
• Flap-Based Reconstructive Surgery
Standard of Care surgical intervention

Locations

Country	Name	City	State
United States	Louisiana State University Health Sciences Center - N.O.	New Orleans	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Louisiana State University Health Sciences Center in New Orleans

Country where clinical trial is conducted

United States, 

References & Publications (20)

Capla JM, Ceradini DJ, Tepper OM, Callaghan MJ, Bhatt KA, Galiano RD, Levine JP, Gurtner GC. Skin graft vascularization involves precisely regulated regression and replacement of endothelial cells through both angiogenesis and vasculogenesis. Plast Reconstr Surg. 2006 Mar;117(3):836-44. — View Citation

Chung KC, Saddawi-Konefka D, Haase SC, Kaul G. A cost-utility analysis of amputation versus salvage for Gustilo type IIIB and IIIC open tibial fractures. Plast Reconstr Surg. 2009 Dec;124(6):1965-73. doi: 10.1097/PRS.0b013e3181bcf156. — View Citation

Colohan S, Saint-Cyr M. Management of lower extremity trauma. In: Plastic Surgery.Vol 4. 3rd ed. Elsevier Inc.; 2013:63-91.

DeFranzo AJ, Argenta LC, Marks MW, Molnar JA, David LR, Webb LX, Ward WG, Teasdall RG. The use of vacuum-assisted closure therapy for the treatment of lower-extremity wounds with exposed bone. Plast Reconstr Surg. 2001 Oct;108(5):1184-91. — View Citation

Godina M. Early microsurgical reconstruction of complex trauma of the extremities. Plast Reconstr Surg. 1986 Sep;78(3):285-92. — View Citation

Gore DC. Outcome and cost analysis for outpatient skin grafting. J Trauma. 1997 Oct;43(4):597-600; discussion 600-2. — View Citation

Gruss JS, Jirsch DW. Human amniotic membrane: a versatile wound dressing. Can Med Assoc J. 1978 May 20;118(10):1237-46. — View Citation

Hong S. Reconstructive surgery: lower extremity coverage. In: Plastic Surgery.Vol 4. 3rd ed. Elsevier Inc.; 2013:127-150.

Hovius SE, Kan HJ, Smit X, Selles RW, Cardoso E, Khouri RK. Extensive percutaneous aponeurotomy and lipografting: a new treatment for Dupuytren disease. Plast Reconstr Surg. 2011 Jul;128(1):221-8. doi: 10.1097/PRS.0b013e31821741ba. — View Citation

Khouri RK, Cooley BC, Kunselman AR, Landis JR, Yeramian P, Ingram D, Natarajan N, Benes CO, Wallemark C. A prospective study of microvascular free-flap surgery and outcome. Plast Reconstr Surg. 1998 Sep;102(3):711-21. — View Citation

Koob TJ, Rennert R, Zabek N, Massee M, Lim JJ, Temenoff JS, Li WW, Gurtner G. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J. 2013 Oct;10(5):493-500. doi: 10.1111/iwj.12140. Epub 2013 Aug 1. — View Citation

Kroll SS, Evans GR, Goldberg D, Wang BG, Reece GP, Miller MJ, Robb GL, Baldwin BJ, Schusterman MA. A comparison of resource costs for head and neck reconstruction with free and pectoralis major flaps. Plast Reconstr Surg. 1997 Apr;99(5):1282-6. — View Citation

MacKenzie EJ, Jones AS, Bosse MJ, Castillo RC, Pollak AN, Webb LX, Swiontkowski MF, Kellam JF, Smith DG, Sanders RW, Jones AL, Starr AJ, McAndrew MP, Patterson BM, Burgess AR. Health-care costs associated with amputation or reconstruction of a limb-threatening injury. J Bone Joint Surg Am. 2007 Aug;89(8):1685-92. — View Citation

Parrett BM, Matros E, Pribaz JJ, Orgill DP. Lower extremity trauma: trends in the management of soft-tissue reconstruction of open tibia-fibula fractures. Plast Reconstr Surg. 2006 Apr;117(4):1315-22; discussion 1323-4. — View Citation

Robson MC, Krizek TJ. The effect of human amniotic membranes on the bacteria population of infected rat burns. Ann Surg. 1973 Feb;177(2):144-9. — View Citation

Serena TE, Carter MJ, Le LT, Sabo MJ, DiMarco DT; EpiFix VLU Study Group. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014 Nov-Dec;22(6):688-93. doi: 10.1111/wrr.12227. Epub 2015 Jan 8. — View Citation

Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2014 Dec;11(6):711-7. doi: 10.1111/iwj.12035. Epub 2013 Feb 15. — View Citation

Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 23-30;276(16):1339-41. Review. — View Citation

Stern M. THE GRAFTING OF PRESERVED AMNIOTIC MEMBRANE TO BURNED AND ULCERATED SURFACES, SUBSTITUING SKIN GRAFTS. JAMA. 1913;60(13):973-974.

Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015 Dec;12(6):724-32. doi: 10.1111/iwj.12395. Epub 2014 Nov 26. — View Citation

* Note: There are 20 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment failure	"Failure" will be defined as a composite of amputation, persistent exposed critical structures, development of osteomyelitis or need for additional flaps within 6 weeks of treatment.; Osteomyelitis will be diagnosed as pus from bone requiring long-term (>4 weeks) of IV antibiotics.),; Experimental Group: "Persistent exposed critical structures" in the experimental arm refers to persistence of exposed nerve, blood vessels, bone or tendon after 4 weeks of dHACM treatment; Standard of care group: Persistence of exposed nerve, blood vessels, bone or tendon after flap treatment	Within 6 weeks of treatment
Secondary	Wound Issue	Were any of the following recorded: wound dehiscence, partial flap loss, or partial skin graft loss requiring prolonged local wound care or other wound treatment (e.g. hyperbaric oxygen therapy, negative pressure wound dressing, other wound devices)?	within 6 months of initial wound closure
Secondary	Epidermolysis	Was there any diagnosis of epidermolysis during study	within 6 months of initial wound closure
Secondary	Length of ICU stay	Total number of ICU inpatient days	within 6 months of initial wound closure
Secondary	Length of inpatient hospital stay	Total number of inpatient hospital days	within 6 months of initial wound closure
Secondary	Total treatment time from initial treatment to initial closure (excludes treatment of complications)	Total number of days from initial treatment to end of study	within 6 months of initial wound closure
Secondary	Total treatment time from initial treatment to completion of limb salvage (includes treatment of complications)	Total number of days from initial treatment to completion of limb salvage	within 6 months of initial wound closure
Secondary	Number of dHACM treatments required	Total number of EpiFix applications	within 6 months of initial wound closure
Secondary	Death from any cause	Death from any cause	within 6 months of initial wound closure
Secondary	Deep vein thrombosis diagnosed by radiologic imaging (e.g. ultrasound or CT)	Any diagnosis of DVT during study	within 6 months of initial wound closure
Secondary	Pulmonary embolus	Any diagnosis of PE during study	within 6 months of initial wound closure
Secondary	Ventilator-associated pneumonia	Any diagnosis of vent-associated pneumonia	within 6 months of initial wound closure
Secondary	Number of microsurgical revisions needed (arterial or venous)	Number of microsurgical revisions needed	within 6 months of initial wound closure
Secondary	Bony non union, bony melanin	Any diagnosis of bony non-union or bony melanin during study	within 6 months of initial wound closure
Secondary	Tendon rupture	Any diagnosis of tendon rupture during study	within 6 months of initial wound closure